Related Experiment Video
Updated: Jan 25, 2026

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer
Maxwell V Meng1, Jürgen E Gschwend2, Neal Shore3
1Department of Urology, University of California, San Francisco, California.
Purpose:
Due to the high rate of recurrence and progression in patients with high risk nonmuscle invasive bladder cancer, there is an important unmet need to identify new therapies. This is particularly true for patients with recurrence after optimal intravesical bacillus Calmette-Guérin therapy, who are classified as having bacillus Calmette-Guérin unresponsive disease.
Materials And Methods:
The PubMed® database was searched for publications related to immunotherapy for the treatment of patients with nonmuscle invasive bladder cancer who have recurrent or progressive disease despite receiving intravesical bacillus Calmette-Guérin therapy. Relevant congress abstracts were identified through searches of individual congress websites. Relevant planned and ongoing studies were identified via ClinicalTrials.gov or associated web searches.
Results:
We provide a summary of the currently available immunotherapy options for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer, and discuss planned and ongoing research of potential targeted agents and immunotherapy based combination regimens.
Conclusions:
There is a clear biological and clinical rationale for the continued evaluation of immune based therapies in the setting of bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. Data from early phase trials with novel immunotherapies targeting multiple immune related pathways have emerged, which support additional studies to assess the benefits of immune checkpoint inhibitors and other immunotherapy based regimens for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Insights
New immunotherapies are needed for high-risk nonmuscle invasive bladder cancer that recurs after bacillus Calmette-Guérin (BCG) therapy. Research is ongoing to evaluate novel agents and combination regimens for BCG-unresponsive bladder cancer.
Area of Science:
- Uro-oncology
- Immunotherapy
- Bladder Cancer Research
Background:
- High-risk nonmuscle invasive bladder cancer (NMIBC) has a significant recurrence and progression rate.
- Patients with BCG-unresponsive NMIBC face limited treatment options.
- There is a critical need for novel therapeutic strategies in this patient population.
Purpose of the Study:
- To review current immunotherapy options for BCG-unresponsive NMIBC.
- To discuss ongoing and planned research into targeted agents and combination immunotherapy regimens.
- To highlight the unmet need for effective treatments in recurrent NMIBC.
Main Methods:
- Systematic literature search of PubMed for immunotherapy in BCG-unresponsive NMIBC.
- Identification of relevant congress abstracts from individual websites.
- Inclusion of planned and ongoing studies from ClinicalTrials.gov.
Main Results:
- Summary of existing immunotherapy treatments for BCG-unresponsive NMIBC.
- Overview of emerging targeted agents and combination immunotherapy trials.
- Identification of research gaps and future directions.
Conclusions:
- Strong biological and clinical rationale supports immune-based therapies for BCG-unresponsive NMIBC.
- Early-phase trial data for novel immunotherapies show promise.
- Further studies are warranted to evaluate immune checkpoint inhibitors and combination regimens.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Emerging Adulthood
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Anatomy of the Genitourinary System II: Bladder and Urethra

